Lyfxon Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 141.52%
- Profit Growth 84.77%
- Ebitda -27.91%
- Net Worth 11.93%
- Total Assets 65.27%
About Lyfxon Lifesciences
Lyfxon Lifesciences Private Limited (LLPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 September 2017 (Seven years and four months 26 days old ). Its registered office is in Kanpur Nagar, Uttar Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mithlesh Gupta and Neeraj Gupta serve as directors at the Company.
Company Details
-
Location
Kanpur Nagar, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24110UP2017PTC097215
-
Company No.
097215
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Sep 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Lyfxon Lifesciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neeraj Gupta
|
Managing Director | 22-Sep-2017 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Mithlesh Gupta
|
Director | 22-Sep-2017 | Current |
Financial Performance of Lyfxon Lifesciences.
Lyfxon Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 141.52% increase. The company also saw a substantial improvement in profitability, with a 84.77% increase in profit. The company's net worth Soared by an impressive increase of 11.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lyfxon Lifesciences?
Unlock access to Lyfxon Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lyfxon Lifesciences?
Unlock and access historical data on people associated with Lyfxon Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lyfxon Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lyfxon Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.